adagrasib (Krazati)
Jump to navigation
Jump to search
Indications
- non-small cell lung carcinoma (NSCLC)
- locally advanced or metastatic NSCLC with KRAS G12C mutations
Dosage
200 mg oral tablet
Adverse effects
- common (>= 20%)
- most common laboratory abnormalities (>= 25%)
- lymphopenia, anemia, thrombocytopenia
- hyponatremia, hypokalemia, hypomagnesemia, increased serum creatinine
- increased serum ALT & serum AST, decreased serum albumin, increased serum lipase
Laboratory
- Agilent Resolution ctDx FIRST Assay (plasma)
- QIAGEN therascreen KRAS RGQ PCR kit (tissue)
* companion diagnostics for Krazati
* if no mutation is detected in a plasma specimen (Agilent), the tumor tissue should be tested (QIAGEN)
Mechanism of action
More general terms
References
- ↑ Food and Drug Administration (FDA) December 12, 2022 FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc
- ↑ Janne PA, Riely GJ, Gadgeel SM et al Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS G12C Mutation N Engl J Med 2022; 387:120-131 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35658005 https://www.nejm.org/doi/full/10.1056/nejmoa2204619
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION Krazati <TM> (adagrasib) tablets, for oral use https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf